Pharmaceutical rivals don’t often come to each other’s defense. But after the US Department of Health and Human Services ...

I downgrade Pfizer to 'Strong Sell' as its high dividend yield fails to offset persistent share price weakness and lack of ...

The FDA approved the poly ADP ribose polymerase (PARP) inhibitor in June 2023 in combination with enzalutamide for men with ...

An experimental treatment by Pfizer and Arvinas delayed progression of breast cancer by more than three months compared to ...

PFE stock offers high dividend yields supported by cost optimizations and R&D. Discover its potential amid COVID-19 sales ...

Although Pfizer has made some efforts to turn things around, they have been insufficient. Pfizer's poor performance since ...

Pfizer's Depo-Provera shot has been linked to brain tumors — and hundreds of women are suing the pharmaceutical giant over it ...

Simply meeting 5% growth estimates with no change in Pfizer's dirt-cheap valuation would produce over 12% annually -- boom, ...

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...

A colorectal cancer drug from Pfizer Inc. doubled survival time compared to the standard of care for a subset of patients, ...

Under the deal, announced on May 20, Pfizer gains the opportunity to develop and sell the SSGJ-707 drug in markets outside of ...

COVID-19 tweets from November 2020 have come back to haunt Pfizer once again. | COVID-19 tweets from November 2020 have come ...